Surgical management of recurrent gynecological cancer: Complete resection is the key to longer survival

Purpose of investigation: This study was conducted to elucidate the efficacy and feasibility of surgical management of recurrent gynecological (cervical, endometrial, and ovarian) cancers. Materials and Methods: Patients undergoing surgical management for recurrent gynecological cancers at Fukushima Medical University between January 2001 and December 2012 were evaluated. Progression-free survival (PFS) and overall survival (OS) were each estimated using the Kaplan-Meier method and compared with the log-rank test. Results: Fifty patients underwent surgery for recurrent gynecological cancers (13 cervical, 18 endometrial, and 19 ovarian). On univariate analysis, complete surgery was a significant prognostic factor in all cancer types. On multivariate analysis, there were significant differences in complete surgery and the number of recurrent tumors for endometrial cancer. Conclusion: These results suggest that, in a select group of patients, especially in recurrent endometrial cancer, surgical management improves survival of recurrent gynecologic cancer patients, and it is valuable therapeutic option.

Recurrent gynecological cancer; Surgical management; Complete surgery

[1] National Comprehensive Cancer Network: “NCCN clinical practice guidelines in oncology cervical cancer V1”, 2016.

[2] Ebina Y., Yaegashi N., Katabuchi H., Nagase S., Udagawa Y., Hachisuga T., et al.: “Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer”. Int. J. Clin. Oncol., 2015, 20, 240.

[3] Colombo N., Carinelli S., Colombo A., Marini C., Rollo D., Sessa C., et al.: “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol., 2012, 23, 27.

[4] Nagase S., Inoue Y., Umesaki N., Aoki D., Ueda M., Sakamoto H., et al.: “Evidence-based guidelines for treatment of cervical cancer in Japan. Japan Society of Gynecologic Oncology (JSGO) 2007 edition”. Int. J. Clin. Oncol., 2010, 15, 117.

[5] Meyer L.A., Bohlke K., Powell M.A., Fader A.N., Franklin G.E., Lee L.J., et al.: “Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline”. J. Clin. Oncol., 2015, 33, 2908.

[6] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol., 2013, 24, 33.

[7] Elshaikh M.A., Vance S., Gaffney DK., Biagioli M., Jhingran A., Jolly S., et al.: “ACR Appropriateness Criteria Management of Recurrent Endometrial Cancer”. Am. J. Clin. Oncol., 2016, 39, 507.

[8] Komiyama S., Katabuchi H., Mikami M., Nagase S., Okamoto A., Ito K., et al.: “Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer”. Int. J. Clin. Oncol., 2016, 21, 435.

[9] Dottino J.A., Cliby W.A., Myers E.R., Bristow R.E., Havrilesky L.J.: “Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention”. Gynecol Oncol., 2015, 138, 694.

[10] Bristow R.E., Chang J., Ziogas A., Campos B., Chavez L.R., AntonCulver H.: “Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival”. J. Am. Coll. Surg., 2015, 220, 940.

[11] Jurado M., Alcázar JL., Martinez-Monge R.: “Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience”. Gynecol. Oncol., 2010, 116(1), 38-43.

[12] Tanaka S., Nagase S., Kaiho-Sakuma M., Nagai T., Kurosawa H., Toyoshima M., et al.: “Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer”. Int. J. Clin Oncol., 2014, 19, 133.

[13] Sardain H., Lavoue V., Redpath M., Bertheuil N., Foucher F., Lev- êque J.: “Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review”. Eur. J. Surg. Oncol., 2015, 41, 975.

[14] Battista M.J., Schmidt M., Eichbaum M., Almstedt K., Heimes AS., Mallmann P., et al.: “Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pat- tern of care studies from the years 2013, 2009 and 2006”. Arch. Gynecol. Obstet., 2015, 292, 1355.

[15] Ren Y., Shan B., Shi D., Wang H.: “Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study”. BMC Cancer, 2014, 26, 135.

[16] Papadia A., Bellati F., Ditto A., Bogani G., Gasparri M.L., Di Donato V., et al.: “Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift”. Ann Surg Oncol., 2015, 22, 4204.

[17] Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al.: “Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial”. Ann. Surg. Oncol., 2006, 13, 1702.

[18] Tian W.J., Chi D.S., Sehouli J., Tropé C.G., Jiang R., Ayhan A., et al.: “A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection”. Ann. Surg. Oncol., 2012, 19, 597.

[19] Popovich M.J., Hricak H., Sugimura K., Stern J.L.: “The role of MR imaging in determining surgical eligibility for pelvic exenteration”. Am. J. Roentgenol.,1993, 160, 525.

[20] Seki M., Nakagawa K., Tsuchiya S., Matsubara T., Kinoshita I., Weng S.Y., et al.: “Surgical treatment of pulmonary metastases from uterine cervical cancer. Operation method by lung tumor size”. J. Thorac. Cardiovasc. Surg., 1992, 104, 876.

[21] Susumu N., Sagae S., Udagawa Y., Niwa K., Kuramoto H., Satoh S., et al.: “Randomised phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study”. Gynecol Oncol., 2008, 108, 226-233.

[22] Randall M.E., Filiaci V.L.., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al.: “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2006, 24, 36.